Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Small Cell Lung Carcinoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Lung Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Docetaxel 17Surveys and Questionnaires 15pembrolizumab 14Specimen Handling 10Radiotherapy 10Early Intervention, Educational 10Zoledronic Acid 9Interviews as Topic 9olaparib 8Standard of Care 8Psychiatric Rehabilitation 8Therapeutics 7Magnetic Resonance Spectroscopy 7Gemcitabine 7Fulvestrant 7durvalumab 6Paclitaxel 6Nivolumab 6Methods 6Educational Status 6Carboplatin 6enzalutamide 5Trastuzumab 5Radiosurgery 5Exercise 5Cyclophosphamide 5palbociclib 4Taxes 4Sirolimus 4Letrozole 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × Dalteparin × Breast × Clear all
NCT00003674 2016-07-13

Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer

Alliance for Clinical Trials in Oncology

Phase 3 Completed
141 enrolled
BreastGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡